Results 31 to 40 of about 15,396 (232)

Histamine-2 receptor antagonist famotidine modulates cardiac stem cell characteristics in hypertensive heart disease [PDF]

open access: yesPeerJ, 2017
Background Cardiac stem cells (CSCs) play a vital role in cardiac homeostasis. A decrease in the efficiency of cardiac stem cells is speculated in various cardiac abnormalities.
Sherin Saheera   +2 more
doaj   +2 more sources

Validação de método espectrofotométrico na região do UV para quantificação de famotidina em cápsulas Validation of an UV spectrophotometric method for quantification of famotidine in capsules

open access: yesQuímica Nova, 2010
This work describes the validation of a method for quantification of famotidine in capsules by UV spectrophotometry using as solvents buffer solution at pH 2.5 and buffer solution at pH 4.5.
Lívia Botacini Favoretto   +4 more
doaj   +1 more source

Simvastatin: A Risk Factor for Angioedema? [PDF]

open access: yes, 2013
Objective. To report a case of simvastatin-induced angioedema in a patient with near nightly episodes of orofacial angioedema. Case Summary. A 75-year-old African American female presented to the emergency department with recurrent face, lip, and tongue ...
Kara, Areeba   +2 more
core   +2 more sources

Effectiveness of oral famotidine in reducing the hematologic complications of radiotherapy in patients with esophageal and cardia cancers: a randomized controlled trial

open access: yesRadiation Oncology, 2023
Background Chemoradiotherapy complications has always been of great concern to both clinicians and patients during the course of treatment. The purpose of the present study was to examine the effectiveness of oral famotidine on the reduction of ...
Mina Rostami   +5 more
doaj   +1 more source

Intravenous Bolus versus Continuous Infusion of Famotidine or Ranitidine on 24 H Intragastric Acidity in Fasting Healthy Volunteers

open access: yesCanadian Journal of Gastroenterology, 1995
Infusions of H2-receptor antagonists may be clinically indicated to maintain intragastric pH above 4 to reduce acute gastric mucosal lesions or to treat patients with bleeding peptic ulcers.
ABR Thomson   +4 more
doaj   +1 more source

Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis. [PDF]

open access: yes, 2018
Diffuse cutaneous mastocytosis (DCM) is a rare but potentially fatal condition when diagnosis and targeted treatments are delayed. This case illustrates the life-threatening complications in DCM and reviews the currently available treatments.
Akin   +32 more
core   +1 more source

Effect of Famotidine on COVID-19: Killing Virus or Opposing ARDS?

open access: yesPulmonary Therapy, 2023
Since the first detection of SARS-CoV-2 in China, COVID-19 (Corona Virus Disease 2019) has taken the lives of more than six million people. Although some antivirals seem proper for treatment, the investigation of finding the best therapeutic approach for
Mahnaz Sadat Hosseini   +3 more
doaj   +1 more source

Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: A meta-analysis [PDF]

open access: yes, 2005
Aim: To systematically evaluate the efficacy of H2-receptor antagonists (H2RAs) and proton pump inhibitors in healing erosive esophagitis (EE). Methods: A meta-analysis was performed.
Huang, JQ   +6 more
core   +1 more source

Design of 3‐aminophenol‐grafted polymer‐modified zinc sulphide nanoparticles as drug delivery system

open access: yesIET Nanobiotechnology, 2021
Zinc sulphide (ZnS) nanoparticles were synthesized by the coprecipitation method. The ZnS nanoparticle surface was polymerized with allyl glycidyl ether (AGE), and 3‐aminophenol was then deposited as a ligand on nanosorbent.
Milad Abniki   +2 more
doaj   +1 more source

Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation [PDF]

open access: yes, 2007
We employed antibody pre-conditioning with alemtuzumab and posttransplant immunosuppression with low-dose tacrolimus monotherapy in 26 consecutive pediatric kidney transplant recipients between January 2004 and December 2005. Mean recipient age was 10.7 ±
Basu, A   +14 more
core   +1 more source

Home - About - Disclaimer - Privacy